|Day Low/High||34.16 / 35.06|
|52 Wk Low/High||14.01 / 39.96|
Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.
A look at possible second-quarter M&A activity in the biotech sector.
You have to be willing to chase if you want to establish new positions.
The Cambridge, Mass.-based firm said Nov. 7 that the U.S. Food and Drug Administration has cleared the investigational new drug application for its peptide phosphorodiamidate morpholino oligomer (PPMO) exon 51 candidate, SRP-5051.
The Menlo Park, Calif.-based firm had a third-quarter net loss of $22 million, compared with $17.5 million in the year-ago period. Product, service and other revenue rose 9% year-over-year to $23.5 million.
Cambridge, Mass.-based KalVista Pharmaceuticals on Oct. 10 unveiled a collaboration pact with Merck.
Pharma and biotech giants now must look to small- and mid-caps to fill out pipelines and bolster growth.